Characteristics and prognostic impact of pneumonitis during systemic anti-cancer therapy in patients with advanced non-small-cell lung cancer

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Fujimoto, Daichi ^a   Kato, Ryoji ^a   Morimoto, Takeshi ^a,b   Shimizu, Ryoko ^a   Sato, Yuki ^a   Kogo, Mariko ^a   Ito, Jiro ^a   Teraoka, Shunsuke ^a   Nagata, Kazuma ^a   Nakagawa, Atsushi ^a   Otsuka, Kojiro ^a   Tomii, Keisuke ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; PACLITAXEL; PEMETREXED; VINORELBINE TARTRATE;

ADVANCED CANCER; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; EGFR GENE; FEMALE; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MORTALITY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING HABIT; SURVIVAL TIME; ADENOCARCINOMA; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 85007283965     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0168465     Document Type: Article

References (45)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64 (1):9-29. Epub 2014/01/09.
2. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: New biological insights and recent therapeutic advances. CA: a cancer journal for clinicians. 2011; 61(2):91-112. Epub 2011/02/10.
3. Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, et al. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. Ann Pharmacother. 2015; 49(4):398-404. Epub 2015/01/08. doi: 10.1177/1060028014566446 PMID: 25565405
4. Dhokarh R, Li G, Schmickl CN, Kashyap R, Assudani J, Limper AH, et al. Drug-associated acute lung injury: a population-based cohort study. Chest. 2012; 142(4):845-50. Epub 2012/04/28. doi: 10.1378/chest.11-2103 PMID: 22539646
5. Minami-Shimmyo Y, Ohe Y, Yamamoto S, Sumi M, Nokihara H, Horinouchi H, et al. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2012; 7(1):177-82. Epub 2011/12/03.
6. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2007; 2(8):706-14. Epub 2007/09/01.
7. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American journal of respiratory and critical care medicine. 2011; 183(6):788-824. Epub 2011/04/08. doi: 10.1164/rccm.2009-040GL PMID: 21471066
8. Nagai Y, Miyazawa H, Huqun, Tanaka T, Udagawa K, Kato M, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer research. 2005; 65 (16):7276-82. Epub 2005/08/18. doi: 10.1158/0008-5472.CAN-05-0331 PMID: 16105816
9. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr., et al. Acute exacerbations of idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine. 2007; 176 (7):636-43. Epub 2007/06/23. doi: 10.1164/rccm.200703-463PP PMID: 17585107
10. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2015; 373(8):782.
11. Camus PH, Foucher P, Bonniaud PH, Ask K. Drug-induced infiltrative lung disease. Eur Respir J Suppl. 2001; 32:93s-100s. Epub 2002/01/31. PMID: 11816828
12. Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2011; 6(7):1242-6. Epub 2011/05/31.
13. Sakurada T, Kakiuchi S, Tajima S, Horinouchi Y, Okada N, Nishisako H, et al. Characteristics of and risk factors for interstitial lung disease induced by chemotherapy for lung cancer. The Annals of pharmacotherapy. 2015; 49(4):398-404. Epub 2015/01/08. doi: 10.1177/1060028014566446 PMID: 25565405
14. Rodrigues G, Lock M, D'Souza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2004; 71(2):127-38. Epub 2004/04/28.
15. Niu X, Li H, Chen Z, Liu Y, Kan M, Zhou D, et al. A study of ethnic differences in TGFbeta1 gene polymorphisms and effects on the risk of radiation pneumonitis in non-small-cell lung cancer. Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer. 2012; 7 (11):1668-75. Epub 2012/10/13.
16. Kim JY, Kim YS, Kim YK, Park HJ, Kim SJ, Kang JH, et al. The TGF-beta1 dynamics during radiation therapy and its correlation to symptomatic radiation pneumonitis in lung cancer patients. Radiat Oncol. 2009; 4:59. Epub 2009/12/01. doi: 10.1186/1748-717X-4-59 PMID: 19943923
17. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008; 133(2):528-38. Epub 2008/02/07. doi: 10.1378/chest.07-0851 PMID: 18252919
18. Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016. Epub 2016/08/19.
19. Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respiratory investigation. 2013; 51(4):260-77. Epub 2013/11/19. doi: 10.1016/j.resinv.2013.09.001 PMID: 24238235
20. Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y, et al. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer. Clinical lung cancer. 2012; 13(4):304-11. Epub 2011/12/16. doi: 10.1016/j.cllc.2011.11.001 PMID: 22169479
21. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. American journal of respiratory and critical care medicine. 2008; 177(12):1348-57. Epub 2008/03/14. doi: 10.1164/rccm.200710-1501OC PMID: 18337594
22. Usui K, Tanai C, Tanaka Y, Noda H, Ishihara T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology. 2011; 16(2):326-31. Epub 2010/12/01. doi: 10.1111/j.1440-1843.2010.01907.x PMID: 21114711
23. Tomassetti S, Gurioli C, Ryu JH, Decker PA, Ravaglia C, Tantalocco P, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015; 147(1):157-64. Epub 2014/08/29. doi: 10.1378/chest.14-0359 PMID: 25166895
24. Isobe K, Hata Y, Sakamoto S, Takai Y, Shibuya K, Homma S. Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology. 2010; 15(1):88-92. Epub 2009/12/02. doi: 10.1111/j.1440-1843.2009.01666.x PMID: 19947998
25. Slatore CG, Cecere LM, Letourneau JL, O'Neil ME, Duckart JP, Wiener RS, et al. Intensive care unit outcomes among patients with lung cancer in the surveillance, epidemiology, and end results-medicare registry. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(14):1686-91. Epub 2012/04/05.
26. Bonomi MR, Smith CB, Mhango G, Wisnivesky JP. Outcomes of elderly patients with stage IIIB-IV nonsmall cell lung cancer admitted to the intensive care unit. Lung Cancer. 2012; 77(3):600-4. Epub 2012/06/20. doi: 10.1016/j.lungcan.2012.05.103 PMID: 22709929
27. Soares M, Toffart AC, Timsit JF, Burghi G, Irrazabal C, Pattison N, et al. Intensive care in patients with lung cancer: a multinational study. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2014; 25(9):1829-35. Epub 2014/06/22.
28. Soares M, Darmon M, Salluh JI, Ferreira CG, Thiery G, Schlemmer B, et al. Prognosis of lung cancer patients with life-threatening complications. Chest. 2007; 131(3):840-6. Epub 2007/03/16. doi: 10.1378/chest.06-2244 PMID: 17356101
29. Fujimoto D, Shimizu R, Morimoto T, Kato R, Sato Y, Kogo M, et al. Analysis of advanced lung cancer patients diagnosed following emergency admission. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2015; 45(4):1098-107. Epub 2014/10/18.
30. Lilenbaum RC. Treatment of advanced non-small-cell lung cancer in special populations. Oncology (Williston Park). 2004; 18(10):1321-5; discussion 6, 9-33. Epub 2004/11/06.
31. Azzoli CG, Baker S Jr., Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(36):6251-66. Epub 2009/11/18.
32. Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, et al. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(23):2849-53. Epub 2013/06/19.
33. Morth C, Valachis A. Single-agent versus combination chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer and performance status 2: a literature-based meta-analysis of randomized studies. Lung Cancer. 2014; 84(3):209-14. Epub 2014/04/08. doi: 10.1016/j.lungcan.2014. 03.015 PMID: 24702946
34. Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA. Implementing and evaluating shared decision making in oncology practice. CA: a cancer journal for clinicians. 2014; 64(6):377-88. Epub 2014/09/10.
35. Katz SJ, Hawley S. The value of sharing treatment decision making with patients: expecting too much? JAMA: the journal of the American Medical Association. 2013; 310(15):1559-60. Epub 2013/09/26. doi: 10.1001/jama.2013.278944 PMID: 24061082
36. Kinoshita T, Azuma K, Sasada T, Okamoto M, Hattori S, Imamura Y, et al. Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncology letters. 2012; 4(3):477-82. Epub 2013/06/07. doi: 10.3892/ol.2012.753 PMID: 23741246
37. Nishino M, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, et al. Interstitial lung abnormalities in treatment-naive advanced non-small-cell lung cancer patients are associated with shorter survival. European journal of radiology. 2015; 84(5):998-1004. Epub 2015/03/03. doi: 10.1016/j.ejrad. 2015.01.021 PMID: 25726730
38. Aubry MC, Myers JL, Douglas WW, Tazelaar HD, Washington Stephens TL, Hartman TE, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clinic proceedings. 2002; 77 (8):763-70. Epub 2002/08/14. PMID: 12173712
39. Ozawa Y, Akahori D, Koda K, Abe T, Hasegawa H, Matsui T, et al. Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer. Cancer chemotherapy and pharmacology. 2016; 77(5):1031-8. Epub 2016/04/07. doi: 10.1007/s00280-016-3025-7 PMID: 27048413
40. Enomoto Y, Inui N, Kato T, Baba T, Karayama M, Nakamura Y, et al. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Lung Cancer. 2016; 96:63-7. Epub 2016/05/03. doi: 10.1016/j.lungcan.2016.03.017 PMID: 27133752
41. Minegishi Y, Kokuho N, Miura Y, Matsumoto M, Miyanaga A, Noro R, et al. Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema. Lung Cancer. 2014; 85(2):258-63. Epub 2014/06/05. doi: 10.1016/j.lungcan.2014.05.016 PMID: 24894326
42. Kenmotsu H, Naito T, Mori K, Ko R, Ono A, Wakuda K, et al. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer chemotherapy and pharmacology. 2015; 75(3):521-6. Epub 2015/01/08. doi: 10.1007/s00280-014-2670-y PMID: 25563718
43. Takeda M, Okamoto I, Nakagawa K. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2015; 88(1):74-9. Epub 2015/02/24. doi: 10.1016/j.lungcan.2015.01.026 PMID: 25704957
44. Yagihashi K, Huckleberry J, Colby TV, Tazelaar HD, Zach J, Sundaram B, et al. Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. The European respiratory journal. 2016; 47 (4):1189-97. Epub 2016/02/27. doi: 10.1183/13993003.01680-2015 PMID: 26917616
45. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction. Thorax. 1999; 54 Suppl 1:S1-14. Epub 2000/09/28.